Present status of agonistic and antagonistic analogs of LH-RH in the treatment of advanced prostate cancer.
The methods for treatment of advanced prostate cancer, based on the agonistic analogs of LH-RH were reviewed. New therapeutic approaches utilizing antagonistic analogs of LH-RH such as SB-75 (Cetrorelix) have been described. Analogs of LH-RH chemically linked to various cytotoxic radicals are also being developed. Combinations of LH-RH agonists or antagonists with superactive somatostatin analogues such as Octastatin (RC-160) or with bombesin/GRP antagonists are being investigated in order to delay or prevent the relapse and improve the therapy for prostate cancer.
Schally
A V
AV
Department of Medicine, Tulane University School of Medicine, New Orleans, LA 70112.
Comaru-Schally
A M
AM
Gonzalez-Barcena
D
D
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001839:Bombesin / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D013004:Somatostatin / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use
D000970:Antineoplastic Agents; C051458:vapreotide; D007987:Gonadotropin-Releasing Hormone; D013004:Somatostatin; C062876:cetrorelix; D001839:Bombesin